Eisai Updates On Long Term Outcomes of Investigational Aβ protofibril antibody lecanemab
Eisai Co., Ltd. announced that an article about long-term health outcomes of its investigational anti-amyloid-beta (Aβ) protofibril antibody lecanemab in people living with early Alzheimer’s disease (AD) using simulation modeling was published in a peer-reviewed journal Neurology and Therapy. In this simulation, lecanemab treatment is estimated to potentially slow the rate of disease progression, maintaining treated […]
